RF313, an orally bioavailable neuropeptide FF receptor antagonist, opposes effects of RF-amide-related peptide-3 and opioid-induced hyperalgesia in rodents.
Elhabazi K, Humbert JP, Bertin I, Quillet R, Utard V, Schneider S, Schmitt M, Bourguignon JJ, Laboureyras E, Ben Boujema M, Simonnet G, Ancel C, Simonneaux V, Beltramo M, Bucher B, Sorg T, Meziane H, Schneider E, Petit-Demoulière B, Ilien B, Bihel F, Simonin F.
Elhabazi K, et al.
Neuropharmacology. 2017 May 15;118:188-198. doi: 10.1016/j.neuropharm.2017.03.012. Epub 2017 Mar 10.
Neuropharmacology. 2017.
PMID: 28288815